US equities |
MU $938.18 ▼-5.14% META $767.37 ▲+3.29% NVDA $225.24 ▼-0.48% SNDK $1,437.63 ▼-3.34% AAPL $345.88 ▲+1.44% SPCX $156.79 ▼-4.05% MSFT $547.92 ▲+1.25% AMD $588.24 ▼-1.01%
FinancialContent

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

0.8718 +0.0149 (+1.74%)
Delayed Quote Updated: 11:00 AM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Cognition Therapeutics Announces Participation in Upcoming September Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics – Could This Company's Technology Make Debilitating Neural Diseases Like Dementia A Thing Of The Past? ↗
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic... 
Via Benzinga
News headline image
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Rises Sharply; Unifirst Earnings Miss Expectations ↗
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.32% to 33,818.48 while the NASDAQ rose 0.23% to 13,586.93. The S&P... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market. 
Via Benzinga
News headline image
Nasdaq Moves Higher; US Crude Stocks Drop More than Projected ↗
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining over 80 points on Wednesday. The Dow traded down 0.42% to 33,784.59 while the NASDAQ rose 0.63% to 13,640.83. The S&P... 
Via Benzinga
News headline image
Why Cognition Therapeutics Stock Is Plunging On Alzheimer's Disease Related News Today ↗
Cognition Therapeutics Inc (NASDAQ: CGTX) announced the topline results from its Phase 2 double-blind, single-crossover SEQUEL study of CT1812 in 16 adults with mild-to-moderate Alzheimer's disease. 
Via Benzinga
News headline image
Dow Drops 100 Points; General Mills Posts Downbeat Sales ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.30% to 33,823.27 while the NASDAQ fell... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
Call and webcast will take place at 8:00am ET 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Dose of Hope: Cognition's CT1812 Proves Its Mettle in Alzheimer's Aβ Oligomer Displacement ↗
Cognition Therapeutics Inc (NASDAQ: CGTX) announces data publication from a Phase 1b SNAP trial of CT1812 to Measure Aβ Oligomer Displacement in Alzheimer's Disease in the 
Via Benzinga
News headline image
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
- First Human Evidence that CT1812 Selectively Engages Aβ Oligomers 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases
International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimer’s Disease, Dementia with Lewy Bodies and Geographic Atrophy 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 23, 2023 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >